169 related articles for article (PubMed ID: 30076956)
1. Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.
Bartos C; Pallagi E; Szabó-Révész P; Ambrus R; Katona G; Kiss T; Rahimi M; Csóka I
Eur J Pharm Sci; 2018 Oct; 123():475-483. PubMed ID: 30076956
[TBL] [Abstract][Full Text] [Related]
2. Interaction Studies Between Levodopa and Different Excipients to Develop Coground Binary Mixtures for Intranasal Application.
Kiss T; Alapi T; Varga G; Bartos C; Ambrus R; Szabó-Révész P; Katona G
J Pharm Sci; 2019 Aug; 108(8):2552-2560. PubMed ID: 30878514
[TBL] [Abstract][Full Text] [Related]
3. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery.
Sharma S; Lohan S; Murthy RS
Drug Dev Ind Pharm; 2014 Jul; 40(7):869-78. PubMed ID: 23600649
[TBL] [Abstract][Full Text] [Related]
4. Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles.
Bartos C; Ambrus R; Sipos P; Budai-Szűcs M; Csányi E; Gáspár R; Márki Á; Seres AB; Sztojkov-Ivanov A; Horváth T; Szabó-Révész P
Int J Pharm; 2015 Aug; 491(1-2):198-207. PubMed ID: 26142244
[TBL] [Abstract][Full Text] [Related]
5. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
[TBL] [Abstract][Full Text] [Related]
6. Report: Preparation of levodopa/carbidopa compound drug resins.
Liu H; Ding H; Zhang D; Fengsi -; Sun C
Pak J Pharm Sci; 2018 Jan; 31(1):205-211. PubMed ID: 29348105
[TBL] [Abstract][Full Text] [Related]
7. Solubility and dissolution rate enhancement of ibuprofen by co-milling with polymeric excipients.
Hussain A; Smith G; Khan KA; Bukhari NI; Pedge NI; Ermolina I
Eur J Pharm Sci; 2018 Oct; 123():395-403. PubMed ID: 30076953
[TBL] [Abstract][Full Text] [Related]
8. Chemical cross-linking: A feasible approach to prolong doxylamine/pyridoxine release from spray-dried chitosan microspheres.
Katsarov P; Pilicheva B; Uzunova Y; Gergov G; Kassarova M
Eur J Pharm Sci; 2018 Oct; 123():387-394. PubMed ID: 30077710
[TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation of clindamycin phosphate loaded chitosan/alginate polyelectrolyte complex film as mucoadhesive drug delivery system for periodontal therapy.
Kilicarslan M; Ilhan M; Inal O; Orhan K
Eur J Pharm Sci; 2018 Oct; 123():441-451. PubMed ID: 30086353
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms.
Goole J; Vanderbist F; Amighi K
Int J Pharm; 2007 Apr; 334(1-2):35-41. PubMed ID: 17097841
[TBL] [Abstract][Full Text] [Related]
11. Design of an interpolyelectrolyte gastroretentive matrix for the site-specific zero-order delivery of levodopa in Parkinson's disease.
Ngwuluka NC; Choonara YE; Modi G; du Toit LC; Kumar P; Ndesendo VM; Pillay V
AAPS PharmSciTech; 2013 Jun; 14(2):605-19. PubMed ID: 23494468
[TBL] [Abstract][Full Text] [Related]
12. Preliminary study of nanonized lamotrigine containing products for nasal powder formulation.
Gieszinger P; Csóka I; Pallagi E; Katona G; Jójárt-Laczkovich O; Szabó-Révész P; Ambrus R
Drug Des Devel Ther; 2017; 11():2453-2466. PubMed ID: 28860716
[TBL] [Abstract][Full Text] [Related]
13. Definition and validation of the Design Space for co-milled nasal powder containing nanosized lamotrigine.
Gieszinger P; Tomuta I; Casian T; Bartos C; Szabó-Révész P; Ambrus R
Drug Dev Ind Pharm; 2018 Oct; 44(10):1622-1630. PubMed ID: 29863907
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.
Ambrus R; Gieszinger P; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Janáky T; Tömösi F; Kecskeméti G; Szabó-Révész P; Bartos C
Molecules; 2020 Feb; 25(5):. PubMed ID: 32120992
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and optimization of preparative variables for controlled-release floating microspheres of levodopa/carbidopa.
Choudhary H; Agrawal AK; Malviya R; Yadav SK; Jaliwala YA; Patil UK
Pharmazie; 2010 Mar; 65(3):194-8. PubMed ID: 20383939
[TBL] [Abstract][Full Text] [Related]
16. Formulation of a dry powder influenza vaccine for nasal delivery.
Garmise RJ; Mar K; Crowder TM; Hwang CR; Ferriter M; Huang J; Mikszta JA; Sullivan VJ; Hickey AJ
AAPS PharmSciTech; 2006 Mar; 7(1):E19. PubMed ID: 16584149
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel ultra cryo-milling technique for a poorly water-soluble drug using dry ice beads and liquid nitrogen.
Sugimoto S; Niwa T; Nakanishi Y; Danjo K
Int J Pharm; 2012 Apr; 426(1-2):162-169. PubMed ID: 22266538
[TBL] [Abstract][Full Text] [Related]
18. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Qiang F; Shin HJ; Lee BJ; Han HK
Int J Pharm; 2012 Jul; 430(1-2):161-6. PubMed ID: 22525082
[TBL] [Abstract][Full Text] [Related]
19. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
20. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
